- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01936012
Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition
Bioequivalence Study of 10 mg Lisinopril Tablets (Lisinopril 10 mg) Produced by PT Dexa Medica in Comparison With The Innovator Tablets (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, Under License From Astra Zeneca UK Ltd.)
Study Overview
Status
Conditions
Detailed Description
This was a randomized, single-blind, two-period, two-sequence, cross-over study under fasting condition. The participating subjects were required to have an overnight fast and in the next morning were given orally one tablet of the test drug (Lisinopril 10 mg, produced by PT Dexa Medica) or one tablet of the reference drug (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, under license from Astra Zeneca UK Ltd.).
Blood samples were drawn immediately before taking the drug (control), and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 24, 36, and 48 hours after drug administration. Seven days after the first drug administration (washout period), the procedure was repeated using the alternate drug.
The pharmacokinetic parameters, including AUCt, AUCinf, Cmax, t max, and t1/2, were determined from plasma concentrations of lisinopril, using liquid chromatography with tandem mass spectrometry detection (LC-MS/MS) method.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jakarta, Indonesia, 12430
- PT Equilab International
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female subjects.
- Aged 18 - 55 years inclusive.
- Non-smokers or moderate smokers (less than 10 cigarettes per day).
- Able to participate, communicate well with the investigators and willing to provide written informed consent to participate in the study.
- Body mass index within 18 to 25 kg/m2.
Vital signs (after 10 minutes rest) were within the following ranges:
- systolic blood pressure 110 - 120 mmHg
- diastolic blood pressure 70 - 80 mmHg
- pulse rate 60 - 90 bpm
Exclusion Criteria:
- Personal/family history of allergy or hypersensitivity or contraindication to lisinopril or allied drugs.
- Pregnant or lactating women.
- Any major illness or clinically significant ongoing chronic medical illness in the past 90 days.
- Any clinically significant abnormality of liver function test (ALT, AP, total bilirubin >= 1.5 ULN).
- Any clinically significant abnormality of renal function test (serum creatinine concentration > 1.4 mg/dL).
- Positive hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV.
- Clinically significant hematology abnormalities.
- Clinically significant electrocardiogram (ECG) abnormalities.
- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug.
- Past history of anaphylaxis or angioedema.
- History of drug or alcohol abuse within 12 months prior to screening.
- Participation in any clinical trial within the past 90 days.
- History of any bleeding or coagulative disorders.
- History of difficulty with donating blood or accessibility of veins in left or right arm.
- A donation or loss of 500 mL (or more) of blood within 3 months before the study's first dosing day.
- Intake of any prescription or non-prescription drugs, food supplements, or herbal medicines within 14 days of the study's first dosing day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lisinopril 10 mg tablets of PT Dexa Medica
Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril.
A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
|
Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril.
Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Other Names:
|
ACTIVE_COMPARATOR: Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia
Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril.
A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
|
Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril.
Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration-time curve from time zero to the last observed quantifiable concentration (AUCt) of lisinopril
Time Frame: 48 hours
|
Relative bioavailability (primarily measured by AUCt and AUCinf) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition.
AUCt was determined from plasma concentration of lisinopril.
|
48 hours
|
Area under the plasma concentration-time curve from time zero to infinity (AUCinf) of lisinopril
Time Frame: 48 hours
|
Relative bioavailability (primarily measured by AUCt and AUCinf) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition.
AUCinf was determined from plasma concentration of lisinopril.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The peak plasma concentration (Cmax) of lisinopril
Time Frame: 48 hours
|
Relative bioavailability (secondarily measured by Cmax) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition.
Cmax was determined from plasma concentration of lisinopril.
|
48 hours
|
Time needed to achieve the peak plasma concentration (t max) of lisinopril
Time Frame: 48 hours
|
Relative bioavailability (secondarily measured by t max) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition.
t max was determined from plasma concentration of lisinopril.
|
48 hours
|
The elimination half-life (t1/2) of lisinopril
Time Frame: 48 hours
|
Relative bioavailability (secondarily measured by t1/2) between two lisinopril 10 mg tablet formulations (test and reference formulations) was assessed under fasting condition.
t1/2 was determined from plasma concentration of lisinopril.
|
48 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BE.258/EQL/2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Lisinopril 10 mg tablets of PT Dexa Medica
-
Dexa Medica GroupCompleted
-
Dexa Medica GroupCompletedGlimepiride BE Study in Healthy Volunteers Under Fasting ConditionIndonesia
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
Dexa Medica GroupCompleted
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
SandozCompleted
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Ayesha De CostaBoston Children's Hospital; Muhimbili University of Health and Allied Sciences and other collaboratorsCompleted